Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Aminothiazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 known ✓ | P29475 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminothiazole SCHEMBL4466019 | 1.00 | ALDH1A1 (0.68) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL28215372 | 0.98 | ALDH1A1 (0.65) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL5907075 | 0.98 | ALDH1A1 (0.65) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL10585434 | 0.93 | ALDH1A1 (0.71) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL27261063 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL28380726 | 0.89 | ALDH1A1 (0.65) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL27899272 | 0.88 | — | — | |
| Aminothiazole SCHEMBL5907076 | 0.87 | ALDH1A1 (0.62) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL28006118 | 0.87 | ALDH1A1 (0.62) | ALDH1A1TSHRNOS1HSD17B10HTT | |
| Aminothiazole SCHEMBL1241596 | 0.86 | ALDH1A1 (0.75) | ALDH1A1TSHRNOS1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720478-A | Side chain synthesis method | 盐城凯利药业有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-106770251-B | Urine analysis test paper and preparation method thereof | 天津果实科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-109651290-B | Preparation method of mirabegron | 安徽省庆云医药股份有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-110845438-B | Synthesis method of 2- (2-aminothiazole-5-yl) -N- [4- (2-chloro-ethyl) -phenyl ] -acetamide | 苏州永健生物医药有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-110845438-A | Synthesis method of 2- (2-aminothiazole-5-yl) -N- [4- (2-chloro-ethyl) -phenyl ] -acetamide | 苏州永健生物医药有限公司 | 2020-02-28 | — | — | CN | claimed |
| CN-104016877-B | Acetylaniline compounds and application thereof in preparation of mirabegron | 南京海融制药有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-104066730-A | Heterocyclic compounds and their use as type III receptor tyrosine kinase modulators | AMBIT BIOSCIENCES CORP | 2014-09-24 | — | — | CN | claimed |
| CN-104016877-A | Acetylaniline compounds and application thereof in preparation of mirabegron | NANJING HAIRONG PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-09-03 | — | — | CN | claimed |
| CN-101824004-B | Synthesization technique for ceftibuten side chain | HUANGSHAN SHEXIAN HONGHUI CHEMICAL CO LTD | 2012-02-22 | — | — | CN | claimed |
| CN-101824004-A | Synthesization technique for ceftibuten side chain | HUANGSHAN SHEXIAN HONGHUI CHEMICAL CO LTD | 2010-09-08 | — | — | CN | claimed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | claimed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | claimed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | claimed |
| EP-0673784-B1 | Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds | XEROX CORP (US) | 1999-10-27 | — | — | EP | claimed |
| JP-3246294-A | — | — | None | — | — | JP | disclosed |
| JP-2028169-A | — | — | None | — | — | JP | disclosed |
| JP-62103093-A | — | — | None | — | — | JP | disclosed |
| EP-0197409-A1 | Cephalosporin derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-15 | — | — | EP | disclosed |
| WO-1986005786-A1 | CEPHALOSPORIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-09 | — | — | WO | disclosed |
| US-4529698-A | Culturing Chromobacterium | E. R. SQUIBB & SONS, INC. (US) | 1985-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | NOS1 3908/4885ALDH1A1 4771/4885TSHR 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.